Additionally it could be demonstrated that VM in NSCLC depends on expression of Sema4D and its receptor plexinB1 which activate RhoA and downstream ROCK, comprising an already known angiogenesis-promoting process in tumors (Basile et al., 2006). The gene discussed is PLXNB1; the disease is non-small cell lung carcinoma.